PE20160520A1 - Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion - Google Patents

Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion

Info

Publication number
PE20160520A1
PE20160520A1 PE2016000096A PE2016000096A PE20160520A1 PE 20160520 A1 PE20160520 A1 PE 20160520A1 PE 2016000096 A PE2016000096 A PE 2016000096A PE 2016000096 A PE2016000096 A PE 2016000096A PE 20160520 A1 PE20160520 A1 PE 20160520A1
Authority
PE
Peru
Prior art keywords
granules
pharmaceutical composition
preparation process
rifapentine
coated tablet
Prior art date
Application number
PE2016000096A
Other languages
English (en)
Inventor
Kumar Shakti
Kumar Ramesh
Prasad Kum
Prajapati Dilip
Khullar Praveen
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51211797&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160520(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20160520A1 publication Critical patent/PE20160520A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica oral de dosis fija para uso en el tratamiento de la tuberculosis, comprendiendo dicha composicion farmaceutica oral: a) granulos que comprenden isoniazid y al menos un excipiente intragranular, b) granulos que comprenden rifapentina y al menos un excipiente intragranular, y c) al menos un excipiente extragranular, y a su proceso de preparacion
PE2016000096A 2013-07-26 2014-07-22 Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion PE20160520A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3341CH2013 2013-07-26

Publications (1)

Publication Number Publication Date
PE20160520A1 true PE20160520A1 (es) 2016-05-31

Family

ID=51211797

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000096A PE20160520A1 (es) 2013-07-26 2014-07-22 Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion

Country Status (18)

Country Link
US (1) US20160158157A1 (es)
EP (1) EP3024443A1 (es)
JP (1) JP6461142B2 (es)
CN (1) CN105407875A (es)
AU (1) AU2014295098B2 (es)
CA (1) CA2918827A1 (es)
CL (1) CL2016000182A1 (es)
EC (1) ECSP16005208A (es)
HK (1) HK1218862A1 (es)
IL (1) IL243368A0 (es)
MX (1) MX2016001154A (es)
PE (1) PE20160520A1 (es)
PH (1) PH12016500120A1 (es)
RU (1) RU2682178C2 (es)
SG (2) SG10201800447UA (es)
TW (1) TWI651084B (es)
WO (1) WO2015011161A1 (es)
ZA (1) ZA201600109B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105407876B (zh) 2013-07-26 2019-08-30 赛诺菲 抗结核病的稳定的包含异烟肼颗粒和利福喷汀颗粒的可分散的片剂及其制备方法
EP3024445B1 (en) 2013-07-26 2019-01-09 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (zh) * 1997-11-26 1999-06-02 岑冠新 复方利福喷丁制剂及制备方法
YU26102A (sh) * 2000-08-09 2004-12-31 Panacea Biotec Limited Nove farmaceutske smese antituberkuloznih lekova i postupak za njihovo dobijanje
WO2002087547A1 (en) * 2001-04-27 2002-11-07 Lupin Limited An improved process for preparation of four-drug anti-tubercular fixed dose combination
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US20090295921A1 (en) * 2005-10-12 2009-12-03 Pioneer Corporation Vehicle-mounted photographing device and method of measuring photographable range of vehicle-mounted camera
CN1857280A (zh) * 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
KR101197277B1 (ko) * 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom

Also Published As

Publication number Publication date
IL243368A0 (en) 2016-02-29
RU2016106384A (ru) 2017-08-29
MX2016001154A (es) 2016-04-29
CL2016000182A1 (es) 2016-06-24
ECSP16005208A (es) 2017-02-24
JP2016539109A (ja) 2016-12-15
TWI651084B (zh) 2019-02-21
WO2015011161A1 (en) 2015-01-29
RU2016106384A3 (es) 2018-05-31
ZA201600109B (en) 2017-04-26
AU2014295098A1 (en) 2016-02-11
RU2682178C2 (ru) 2019-03-15
TW201605442A (zh) 2016-02-16
PH12016500120A1 (en) 2016-04-25
SG11201510730UA (en) 2016-01-28
HK1218862A1 (zh) 2017-03-17
EP3024443A1 (en) 2016-06-01
JP6461142B2 (ja) 2019-01-30
SG10201800447UA (en) 2018-02-27
AU2014295098B2 (en) 2019-07-11
CA2918827A1 (en) 2015-01-29
CN105407875A (zh) 2016-03-16
US20160158157A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112012028091A2 (pt) composições farmacêuticas compreendendo pioglitazona e linagliptina
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
CR20120549A (es) Composiciones farmacèuticas que comprenden hidromorfona y naloxona
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
PE20151607A1 (es) Formulaciones de compuestos organicos
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
CL2016000397A1 (es) Tratamiento contra el cáncer
BR112016007031A8 (pt) composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida
UY37518A (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
EA201200799A1 (ru) Гепатопротекторное средство